Trial of paracetamol for premature newborns: five-year follow-up
| Autor: | Outi Aikio, Timo Saarela, Sanna Juujärvi, Mikko Hallman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
congenital
hereditary and neonatal diseases and abnormalities Pediatrics medicine.medical_specialty Pain medication Infant Premature Diseases Outcome assessment law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law 030225 pediatrics Ductus arteriosus medicine Humans Infant Very Low Birth Weight cardiovascular diseases 030212 general & internal medicine Child Ductus Arteriosus Patent Acetaminophen business.industry Five year follow up Infant Newborn Obstetrics and Gynecology Infant medicine.anatomical_structure embryonic structures Pediatrics Perinatology and Child Health cardiovascular system Long Term Adverse Effects business Infant Premature medicine.drug Follow-Up Studies |
| Zdroj: | The journal of maternal-fetalneonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 35(25) |
| ISSN: | 1476-4954 |
| Popis: | Paracetamol is a commonly used pain medication for the very-high risk neonates and it is increasingly being used for patent ductus arteriosus treatment in preterm infants. However, randomized trial data on long-term consequences are not yet available, but there is some evidence of serious adverse effects on children exposed to paracetamol during pregnancy.A five-year follow-up study of a placebo-controlled paracetamol trial on very preterm infants (PreParaS) was conducted (Most parents reported that their child had normal development (paracetamol 79% vs. placebo 65%). Physician-diagnosed asthma or allergy (paracetamol 10.5% vs. placebo 25.0%), or hospitalization due to respiratory symptoms (0 vs. 15%) were uncommon and neurological or neuro-psychiatric symptoms were rare.Current follow-up results on paracetamol-exposed very preterm infants may not be alarming suggesting that paracetamol administration shortly after birth is not associated with common adverse consequences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|